Zhende Medical(SH:603301)2025-01-21 09:00Financial Performance Forecast - The company expects a net profit attributable to shareholders for 2024 to be between RMB 373 million and RMB 393 million, representing an increase of 88.00% to 98.09% compared to the previous year[2]. - The projected net profit after deducting non-recurring gains and losses is estimated to be between RMB 303 million and RMB 323 million, an increase of 59.82% to 70.37% year-on-year[3]. - The company anticipates total revenue for 2024 to be between RMB 4.2 billion and RMB 4.3 billion, reflecting a growth of 1.77% to 4.19% compared to the previous year[6]. Revenue Breakdown - Revenue from isolation protective products is expected to decline to between RMB 150 million and RMB 170 million, a decrease of 70.85% to 74.28% from RMB 583.2 million in the previous year[7]. - Revenue excluding isolation protective products is projected to be between RMB 4.05 billion and RMB 4.13 billion, an increase of 14.28% to 16.54% compared to RMB 3.54 billion in the previous year[7]. Gross Profit Expectations - The gross profit from isolation protective products is expected to be between RMB 60 million and RMB 70 million, down 74.20% to 77.89% from RMB 271.34 million last year[7]. - The gross profit from core business excluding isolation protective products is projected to be between RMB 1.36 billion and RMB 1.42 billion, an increase of 17.13% to 22.30% compared to RMB 1.1611 billion in the previous year[7]. Non-Operating Gains and Impairment Tests - The increase in non-operating gains is expected to be approximately RMB 60 million due to asset disposal gains from land use rights[6]. - The company has conducted impairment tests on inventory and production equipment, leading to a low performance base for 2023[6]. Performance Forecast Accuracy - There are no significant uncertainties that could affect the accuracy of this performance forecast[9].